Z
Zenas BioPharma, Inc. (ZBIO)
NMS – Real Time Price. Currency in USD
19.16
-1.24 (-6.08%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
19.16
-1.24 (-6.08%)
At close: May 12, 2026, 4:00 PM EDT
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Haley Laken Ph.D. | Chief Scientific Officer |
| Dr. Heinrich Schlieker Ph.D. | Chief Technical Officer |
| Dr. Lisa von Moltke M.D. | Head of Research & Development and Chief Medical Officer |
| Mr. Jeffrey Held | Chief Legal Officer |
| Mr. Joseph L. Farmer | COO & President |
| Mr. Leon Oliver Moulder Jr., M.B.A. | Founder, CEO & Chairman |
| Ms. Caroline Chevalier | Chief Administrative Officer |
| Ms. Jennifer A. Fox | Chief Business Officer & CFO |
| Date | Type | Document |
|---|---|---|
| 2026-03-31 | 8-K | tm2610711d1_8k.htm |
| 2026-03-16 | DEFA14A | tm261625d3_defa14a.htm |
| 2026-03-16 | DEF 14A | tm261625-1_def14a.htm |
| 2026-02-13 | 8-K | tm266357d1_8k.htm |
| 2026-01-05 | 8-K | tm261774d1_8k.htm |
| 2025-12-19 | S-8 | tm2533836d1_s8.htm |
| 2025-12-15 | 8-K | tm2533427d1_8k.htm |
| 2025-11-12 | 8-K | tm2530850d1_8k.htm |
| 2025-10-27 | 8-K | tm2529508d1_8k.htm |
| 2025-10-21 | S-3ASR | tm2529075-1_s3asr.htm |